The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure
DOI10.1093/BIOSTATISTICS/3.4.547zbMATH Open1138.62354OpenAlexW2107399871WikidataQ47670957 ScholiaQ47670957MaRDI QIDQ5701166FDOQ5701166
Authors: Ngayee J. Law, Howard M. Sandler, Jeremy M. G. Taylor 
Publication date: 2 November 2005
Published in: Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biostatistics/3.4.547
Recommendations
- scientific article; zbMATH DE number 2222299
- Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model
- A new joint model for longitudinal and survival data with a cure fraction
- Joint modeling of longitudinal proportional measurements and survival time with a cure fraction
- Joint modeling of longitudinal and cure-survival data
Monte Carlo EMSurvival analysisProstate cancerLongitudinal modelsCure modelsProstate specific antigen
Estimation in survival analysis and censored data (62N02) Applications of statistics to biology and medical sciences; meta analysis (62P10) Monte Carlo methods (65C05) Medical applications (general) (92C50)
Cited In (27)
- Finite sample and asymptotic distributions of a statistic for sufficient follow-up in cure models
- A comparative study of approaches for predicting prostate cancer from longitudinal data
- Analysis of longitudinal and survival data: joint modeling, inference methods, and issues
- Semiparametric Modeling of Longitudinal Measurements and Time‐to‐Event Data–A Two‐Stage Regression Calibration Approach
- Biomarker-based precision dose finding for immunotherapy combined with radiotherapy
- Analysis of joint multiple failure mode and linear degradation data with renewals
- Joint modeling of longitudinal and cure-survival data
- Bayesian Influence Measures for Joint Models for Longitudinal and Survival Data
- Modeling Disease Progression With Longitudinal Markers
- Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks
- Mixture cure rate models with neural network estimated nonparametric components
- A stochastic model for prostate-specific antigen levels
- Semiparametric Bayesian joint models of multivariate longitudinal and survival data
- BILITE: a Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy
- A characterization of missingness at random in a generalized shared-parameter joint modeling framework for longitudinal and time-to-event data, and sensitivity analysis
- Predictive comparison of joint longitudinal-survival modeling: a case study illustrating competing approaches
- Estimation of reliability using failure-degradation data with explanatory variables
- A new approach for joint modelling of longitudinal measurements and survival times with a cure fraction
- Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model
- A stochastic model for PSA levels: behavior of solutions and population statistics
- Frequentist and Bayesian approaches for a joint model for prostate cancer risk and longitudinal prostate-specific antigen data
- A Bayesian semiparametric survival model with longitudinal markers
- Mixture cure model methodology in survival analysis: some recent results for the one-sample case
- Bayesian approaches to joint cure-rate and longitudinal models with applications to cancer vaccine trials
- Random Changepoint Model for Joint Modeling of Cognitive Decline and Dementia
- A new joint model for longitudinal and survival data with a cure fraction
- Joint modeling of longitudinal and time-to-event data on multivariate protein biomarkers
This page was built for publication: The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5701166)
